B. Riley Securities resumed coverage on Augmedix with a new price target
$AUGX
Business Services
Consumer Discretionary
B. Riley Securities resumed coverage of Augmedix with a rating of Buy and set a new price target of $5.50
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/22/2024 | Buy → Hold | Lake Street | |
| 7/22/2024 | $3.00 → $2.35 | Buy → Neutral | B. Riley Securities |
| 5/14/2024 | $5.00 | Buy → Hold | Maxim Group |
| 5/14/2024 | $5.00 → $1.50 | Outperform → In-line | Evercore ISI |
| 4/3/2024 | $5.50 | Buy | B. Riley Securities |
| 12/15/2023 | $6.00 | In-line | Evercore ISI |
| 3/7/2022 | $6.00 | Buy | Lake Street |
| 1/21/2022 | $6.00 | Buy | Maxim Group |
4 - Augmedix, Inc. (0001769804) (Issuer)
4 - Augmedix, Inc. (0001769804) (Issuer)
4 - Augmedix, Inc. (0001769804) (Issuer)
Lake Street downgraded Augmedix from Buy to Hold
B. Riley Securities downgraded Augmedix from Buy to Neutral and set a new price target of $2.35 from $3.00 previously
Maxim Group downgraded Augmedix from Buy to Hold and set a new price target of $5.00
SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Commure, a healthcare technology company, announced today that it has completed the acquisition of Augmedix. Augmedix will now operate as a wholly-owned subsidiary of Commure. The merger was previously announced on July 19, 2024, and was approved by Augmedix stockholders at Augmedix's special meeting of stockholders held on September 27, 2024. With the completion of the acquisition, Augmedix stockholders are entitled to $2.35 in cash for each share of Augmedix common stock they owned immediately prior to the closing. Augmedix's stock has ceased trading and will be delisted from the Nasdaq Stock Market. "I started Augmedix to relieve clinic
SAN FRANCISCO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended June 30, 2024. "We believe we are approaching the proposed combination with Commure, Inc. from a position of strength, with consistent double-digit revenue growth and improving gross margins," commented Manny Krakaris, Augmedix CEO. "Together, we believe we will be well-positioned to continue to streamline the medical documentation ecosystem with a growing base of health system customers, solid partners, and proven solutions. As part of Commure, we expect to scale our ambient documentation solu
SAN FRANCISCO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, announced today it anticipates releasing second quarter 2024 results after the market closes on Monday, August 12, 2024. On July 19, 2024, Augmedix announced that it entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems. Due to this pending acquisition, management is not hosting a quarterly conference call. About Augmedix Augmedix (NASDAQ:AUGX) empowers clinicians to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and
4 - Augmedix, Inc. (0001769804) (Issuer)
4 - Augmedix, Inc. (0001769804) (Issuer)
15-12G - Augmedix, Inc. (0001769804) (Filer)
EFFECT - Augmedix, Inc. (0001769804) (Filer)
EFFECT - Augmedix, Inc. (0001769804) (Filer)
SAN FRANCISCO, July 19, 2024 (GLOBE NEWSWIRE) -- Augmedix, Inc. (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today announced that it has entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems, in an all-cash transaction that values Augmedix at approximately $139 million in equity value. Under the terms of the agreement, Augmedix stockholders will receive $2.35 per share in cash upon completion of the proposed transaction, and Augmedix will become a wholly-owned subsidiary of Commure. The purchase price represents a premium of approximately 169% over the volume weighted average price
SAN FRANCISCO, May 29, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient artificial intelligence (AI) medical documentation and data solutions, today announced that Alex Stinard, M.D., has been named Chief Clinical AI Officer of the company. Dr. Stinard brings over two decades of extensive experience as an emergency medicine clinician. He has a background in data science with a specialization in large language models, computer vision, and natural language processing. This mix of experience makes Dr. Stinard uniquely qualified for this new position. "Welcoming Dr. Stinard to join Augmedix in this new role is an exciting step forward in implementing advanced AI technolog
SAN FRANCISCO, April 04, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today announced its go-to-market partnership with SADA, an Insight company, a leading cloud business and technology consultancy. The collaboration is focused on leveraging the companies' combined technology expertise and expanding their reach to provide greater product and service value to health systems seeking high-quality ambient documentation and structured data products. "We are thrilled to join forces with SADA, to partner with an organization that has a nationwide reach to health systems, and also to leverage their prowess in frontier cloud infr
SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Commure, a healthcare technology company, announced today that it has completed the acquisition of Augmedix. Augmedix will now operate as a wholly-owned subsidiary of Commure. The merger was previously announced on July 19, 2024, and was approved by Augmedix stockholders at Augmedix's special meeting of stockholders held on September 27, 2024. With the completion of the acquisition, Augmedix stockholders are entitled to $2.35 in cash for each share of Augmedix common stock they owned immediately prior to the closing. Augmedix's stock has ceased trading and will be delisted from the Nasdaq Stock Market. "I started Augmedix to relieve clinic
SAN FRANCISCO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, announced today it anticipates releasing second quarter 2024 results after the market closes on Monday, August 12, 2024. On July 19, 2024, Augmedix announced that it entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems. Due to this pending acquisition, management is not hosting a quarterly conference call. About Augmedix Augmedix (NASDAQ:AUGX) empowers clinicians to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and
SAN FRANCISCO, May 13, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended March 31, 2024. "Augmedix delivered in-line first quarter performance, with 40% revenue growth, 143% net revenue retention and 47.1% gross margins," commented Manny Krakaris, Augmedix CEO. "We are confident about our positioning within the medical documentation market, and expect to report continued growth throughout the rest of the year. It is now clear, however, that health systems are proceeding methodically while they develop a better understanding of the capabilities of AI products." "We a
SC 13D/A - Augmedix, Inc. (0001769804) (Subject)
SC 13G - Augmedix, Inc. (0001769804) (Subject)
SC 13D/A - Augmedix, Inc. (0001769804) (Subject)